High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study
et al., Frontiers in Pharmacology,
PSM retrospective 110 patients, 55 treated with high-dose IV vitamin C, showing lower progression to severe disease with treatment. Patients in each group were in different time periods, time based confounding is likely due to SOC improving over time. ChiCTR2000033050.
risk of progression, 72.0% lower, RR 0.28, p = 0.03, treatment 4 of 55 (7.3%), control 12 of 55 (21.8%), NNT 6.9, adjusted per study, PSM.
time to viral-, 7.7% higher, relative time 1.08, p = 0.79, treatment 55, control 55, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta
substantial confounding by time
likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
Zhao et al., 22 Apr 2021, retrospective, propensity score matching, China, peer-reviewed, 15 authors, average treatment delay 4.0 days.